Search / 82 results found

from
to

TORONTO, Nov. 30, 2021 /PRNewswire/ -- Lighthouse Immersive, North America's leading producer of ground-breaking experiential art exhibits, today announces its newest immersive art installation, FRIDA: IMMERSIVE DREAM. On the heels of its critically acclaimed blockbuster Immersive Van Gogh (now on-view in 15 cities), the Lighthouse Immersive team has set their sights on the art and life of Frida Kahlo (1907-1954), the beloved 20th century Mexican artist best known for compelling self-portraits and radiant pieces inspired by her life in her native country of Mexico. The exhibition features some of the artist's best-known works "brought to life" by the world-renowned master of digital art, Italy's Massimiliano Siccardi, again accompanied by composer Luca Longobardi's resonant score. Vittorio Guidotti is the Art Director. A brilliant, bold and uncompromising painter, Kahlo's work is globally recognized for its raw emotional vitality, vibrant color work and unflinching intimacy. FRIDA: IMMERSIVE DREAM arrives Spring 2022 in the following cities: 

  • Updated

VANCOUVER, BC and HOUSTON, Nov. 23, 2021 /PRNewswire/ -- Woodfibre LNG has signed an Engineering, Procurement, Fabrication, and Construction (EPFC) contract with McDermott International. The EPFC contract is an important step in advancing detailed engineering and construction scheduling work in advance of Woodfibre LNG issuing a notice to proceed.

  • Updated

VANCOUVER, Canada and HOUSTON, Texas, Nov. 18, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2021. All references to "$" in this release refer to United States dollars, unless otherwise indicated.

  • Updated

VANCOUVER, Canada and HOUSTON, Texas, Nov. 18, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2021. All references to "$" in this release refer to United States dollars, unless otherwise indicated.